RT Journal Article
SR Electronic
T1 An inflammatory cytokine signature helps predict COVID-19 severity and death
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.28.20115758
DO 10.1101/2020.05.28.20115758
A1 Valle, Diane Marie Del
A1 Kim-Schulze, Seunghee
A1 Huang, Hsin-Hui
A1 Beckmann, Noam
A1 Nirenberg, Sharon
A1 Wang, Bo
A1 Lavin, Yonit
A1 Swartz, Talia
A1 Madduri, Deepu
A1 Stock, Aryeh
A1 Marron, Thomas U.
A1 Xie, Hui
A1 Patel, Manishkumar
A1 Oekelen, Oliver van
A1 Rahman, Adeeb
A1 Kovatch, Patricia
A1 Aberg, Judith A.
A1 Schadt, Eric
A1 Jagannath, Sundar
A1 Mazumdar, Madhu
A1 Charney, Alexander
A1 Firpo-Betancourt, Adolfo
A1 Rao Mendu, Damodara
A1 Jhang, Jeffrey
A1 Reich, David
A1 Sigel, Keith
A1 Cordon-Cardo, Carlos
A1 Feldmann, Marc
A1 Parekh, Samir
A1 Merad, Miriam
A1 Gnjatic, Sacha
YR 2020
UL http://medrxiv.org/content/early/2020/05/30/2020.05.28.20115758.abstract
AB The COVID-19 pandemic caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has led to more than 100,000 deaths in the United States. Several studies have revealed that the hyper-inflammatory response induced by SARS-CoV-2 is a major cause of disease severity and death in infected patients. However, predictive biomarkers of pathogenic inflammation to help guide targetable immune pathways are critically lacking. We implemented a rapid multiplex cytokine assay to measure serum IL-6, IL-8, TNF-α, and IL-1β in hospitalized COVID-19 patients upon admission to the Mount Sinai Health System in New York. Patients (n = 1484) were followed up to 41 days (median 8 days) and clinical information, laboratory test results and patient outcomes were collected. In 244 patients, cytokine measurements were repeated over time, and effect of drugs could be assessed. Kaplan-Meier methods were used to compare survival by cytokine strata, followed by Cox regression models to evaluate the independent predictive value of baseline cytokines. We found that high serum IL-6, IL-8, and TNF-α levels at the time of hospitalization were strong and independent predictors of patient survival. Importantly, when adjusting for disease severity score, common laboratory inflammation markers, hypoxia and other vitals, demographics, and a range of comorbidities, IL-6 and TNF-α serum levels remained independent and significant predictors of disease severity and death. We propose that serum IL-6 and TNF-α levels should be considered in the management and treatment of COVID-19 patients to stratify prospective clinical trials, guide resource allocation and inform therapeutic options. We also propose that patients with high IL-6 and TNF-α levels should be assessed for combinatorial blockade of pathogenic inflammation in this disease.Competing Interest StatementS.G. reports consultancy and/or advisory roles for Merck, Neon Therapeutics and OncoMed and research funding from Bristol-Myers Squibb, Genentech, Immune Design, Agenus, Janssen R&D, Pfizer, Takeda, and Regeneron.Funding StatementS.G., D.M.D.V.. S.K.-S., P.K., A.R. and M.M. were supported by NCI U24 grant CA224319. S.G. is additionally supported by grants U01 DK124165 and P01 CA190174. M.M. was supported by the fast-grant fund. The Human Immune Monitoring Center and the Institute for Healthcare Delivery Science received support from Cancer Center P30 grant CA196521.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Mount Sinai Institutional Review Board. A waiver of informed consent was obtained to query the patient electronic medical record. Samples for the RT-PCR SARS-CoV-2 lab test were collected via nasopharyngeal or oropharyngeal swab at one of 53 different Mount Sinai locations, representing outpatient, urgent care, emergency and inpatient facilities. Blood specimen for ELLA were collected via venipuncture within the MSHS. All specimen and imaging were collected as part of standard of care.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets analyzed during the current study are not publicly available due to United States Federal Health Insurance Portability and Accountability Act (HIPAA) compliance. A de-identified dataset may be available from the corresponding author on reasonable request.